No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARVN Arvinas
- 24.820
- -0.120-0.48%
Close Jun 18 16:00 ET
- 24.584
- -0.236-0.95%
Post 19:29 ET
1.70BMarket Cap-4102P/E (TTM)
25.230High24.590Low653.62KVolume24.790Open24.940Pre Close16.30MTurnover1.15%Turnover RatioLossP/E (Static)68.43MShares53.08052wk High2.79P/B1.41BFloat Cap13.57052wk Low--Dividend TTM56.91MShs Float108.465Historical High--Div YieldTTM2.57%Amplitude10.190Historical Low24.938Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Arvinas Inc - Company's Obligations Under Original Agreement to Pay Yale Minimum Annual Royalties and Certain Other Annual Fees Have Been Eliminated
Express News | Arvinas Inc - Will Make Another $5.0 Mln Payment on First Anniversary of Signing
Express News | Arvinas Inc - in Connection With Signing of Amended License Agreement, Company Made a Payment of $14.95 Mln to Yale
Express News | Arvinas Inc - on June 14 Unit Entered Into an Amended and Restated License Agreement With Yale University
Express News | Arvinas Announces Promotions of Ian Taylor, Ph.d. to President of Research and Development and Angela Cacace, Ph.d. to Chief Scientific Officer
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announce
Comments
Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28% 1
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
1
$Arvinas(ARVN.US$ 👀 new hoy
$Arvinas(ARVN.US$ I hope everyone bought that sub 14 dip! This thing has been a beast.
1
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg